Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 79 | 2024 | 2371 | 10.430 |
Why?
|
Quinolines | 15 | 2024 | 769 | 4.530 |
Why?
|
Phenylurea Compounds | 17 | 2024 | 536 | 4.490 |
Why?
|
Proto-Oncogene Proteins c-ret | 18 | 2024 | 228 | 4.290 |
Why?
|
Iodine Radioisotopes | 26 | 2024 | 1029 | 3.750 |
Why?
|
Carcinoma, Neuroendocrine | 17 | 2024 | 341 | 3.630 |
Why?
|
Head and Neck Neoplasms | 45 | 2025 | 2921 | 2.690 |
Why?
|
Protein Kinase Inhibitors | 32 | 2024 | 5696 | 2.470 |
Why?
|
Pyrazoles | 15 | 2024 | 2033 | 2.170 |
Why?
|
Carcinoma, Squamous Cell | 39 | 2019 | 4044 | 2.050 |
Why?
|
Pyridines | 20 | 2024 | 2888 | 1.790 |
Why?
|
Radiation Tolerance | 9 | 2021 | 475 | 1.700 |
Why?
|
Oncogene Proteins, Fusion | 6 | 2024 | 1608 | 1.620 |
Why?
|
Antineoplastic Agents | 42 | 2024 | 13648 | 1.570 |
Why?
|
Proto-Oncogene Proteins B-raf | 12 | 2022 | 2054 | 1.320 |
Why?
|
Carcinoma | 9 | 2020 | 2312 | 1.200 |
Why?
|
Anilides | 9 | 2024 | 415 | 1.130 |
Why?
|
Oropharyngeal Neoplasms | 5 | 2022 | 492 | 1.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 28 | 2024 | 11868 | 1.070 |
Why?
|
Carcinoma, Papillary | 9 | 2022 | 788 | 1.040 |
Why?
|
Receptor, trkA | 6 | 2024 | 159 | 0.900 |
Why?
|
Indazoles | 2 | 2024 | 303 | 0.900 |
Why?
|
Adenoma, Oxyphilic | 4 | 2024 | 149 | 0.900 |
Why?
|
Lung Neoplasms | 14 | 2024 | 13451 | 0.890 |
Why?
|
Papillomavirus Infections | 8 | 2022 | 1640 | 0.860 |
Why?
|
Carcinoma, Medullary | 6 | 2023 | 114 | 0.850 |
Why?
|
Neoplasms, Squamous Cell | 4 | 2012 | 95 | 0.850 |
Why?
|
Molecular Targeted Therapy | 8 | 2021 | 2822 | 0.840 |
Why?
|
Adenocarcinoma, Follicular | 4 | 2024 | 326 | 0.770 |
Why?
|
Adenocarcinoma | 7 | 2024 | 6364 | 0.740 |
Why?
|
Quinazolines | 8 | 2024 | 1364 | 0.700 |
Why?
|
Mutation | 26 | 2024 | 30198 | 0.660 |
Why?
|
Papillomaviridae | 5 | 2022 | 1141 | 0.650 |
Why?
|
Neoplasm Metastasis | 18 | 2025 | 4893 | 0.640 |
Why?
|
Lymphocyte Count | 1 | 2021 | 790 | 0.620 |
Why?
|
Mouth Neoplasms | 3 | 2017 | 594 | 0.590 |
Why?
|
Pyrimidines | 5 | 2024 | 3047 | 0.570 |
Why?
|
Thyroid Nodule | 4 | 2021 | 779 | 0.560 |
Why?
|
Leukocyte Count | 1 | 2021 | 1602 | 0.550 |
Why?
|
Carcinoma, Adenoid Cystic | 5 | 2024 | 263 | 0.530 |
Why?
|
Thyroid Gland | 5 | 2023 | 1180 | 0.520 |
Why?
|
Humans | 170 | 2025 | 765968 | 0.510 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2025 | 9373 | 0.490 |
Why?
|
Sulfonamides | 4 | 2016 | 1984 | 0.470 |
Why?
|
Gene Fusion | 4 | 2023 | 357 | 0.470 |
Why?
|
Indoles | 6 | 2016 | 1839 | 0.470 |
Why?
|
Respiratory Rate | 1 | 2016 | 179 | 0.460 |
Why?
|
Cell Differentiation | 6 | 2024 | 11641 | 0.460 |
Why?
|
Niacinamide | 6 | 2015 | 419 | 0.450 |
Why?
|
Thyroidectomy | 10 | 2024 | 916 | 0.450 |
Why?
|
Combined Modality Therapy | 21 | 2021 | 8529 | 0.450 |
Why?
|
Carboplatin | 10 | 2024 | 789 | 0.410 |
Why?
|
Aged | 69 | 2025 | 171117 | 0.400 |
Why?
|
Genes, Neoplasm | 1 | 2014 | 370 | 0.390 |
Why?
|
Treatment Outcome | 38 | 2025 | 65188 | 0.380 |
Why?
|
Infratentorial Neoplasms | 1 | 2012 | 94 | 0.380 |
Why?
|
Chemoprevention | 1 | 2014 | 327 | 0.370 |
Why?
|
Middle Aged | 77 | 2025 | 223009 | 0.370 |
Why?
|
Acoustic Stimulation | 1 | 2016 | 1255 | 0.370 |
Why?
|
Male | 90 | 2025 | 363698 | 0.360 |
Why?
|
Pyrroles | 3 | 2014 | 1119 | 0.360 |
Why?
|
Clinical Trials as Topic | 7 | 2019 | 8041 | 0.360 |
Why?
|
Salivary Gland Neoplasms | 3 | 2021 | 305 | 0.350 |
Why?
|
Gene Rearrangement | 3 | 2021 | 1144 | 0.340 |
Why?
|
Female | 91 | 2025 | 396112 | 0.340 |
Why?
|
Paranasal Sinuses | 1 | 2012 | 267 | 0.330 |
Why?
|
Double-Blind Method | 13 | 2024 | 12437 | 0.320 |
Why?
|
Taxoids | 9 | 2016 | 665 | 0.320 |
Why?
|
Carcinoid Tumor | 2 | 2014 | 225 | 0.300 |
Why?
|
Neutrophils | 1 | 2021 | 3776 | 0.300 |
Why?
|
Aged, 80 and over | 30 | 2025 | 59489 | 0.300 |
Why?
|
Monitoring, Physiologic | 1 | 2016 | 1792 | 0.300 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2024 | 5337 | 0.270 |
Why?
|
Adult | 57 | 2024 | 223044 | 0.270 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 4 | 2017 | 660 | 0.270 |
Why?
|
Benzamides | 2 | 2024 | 1377 | 0.270 |
Why?
|
Kaplan-Meier Estimate | 10 | 2020 | 6499 | 0.270 |
Why?
|
Carcinoma, Ductal | 2 | 2020 | 97 | 0.260 |
Why?
|
Imidazoles | 3 | 2020 | 1162 | 0.260 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2006 | 90 | 0.260 |
Why?
|
Infant, Premature | 1 | 2016 | 2122 | 0.260 |
Why?
|
Piperidines | 5 | 2024 | 1664 | 0.250 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2015 | 784 | 0.250 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 561 | 0.250 |
Why?
|
Tumor Burden | 2 | 2022 | 1885 | 0.250 |
Why?
|
Neoplasms | 10 | 2023 | 22340 | 0.250 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2895 | 0.240 |
Why?
|
Medical Oncology | 6 | 2022 | 2339 | 0.230 |
Why?
|
Herpesvirus 4, Human | 3 | 2024 | 1078 | 0.230 |
Why?
|
Heart Rate | 1 | 2016 | 4204 | 0.230 |
Why?
|
Disease-Free Survival | 15 | 2018 | 6832 | 0.230 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2024 | 1801 | 0.220 |
Why?
|
Nasopharyngeal Neoplasms | 3 | 2024 | 296 | 0.220 |
Why?
|
Diarrhea | 3 | 2022 | 1316 | 0.220 |
Why?
|
Laryngeal Neoplasms | 3 | 2018 | 512 | 0.220 |
Why?
|
Disease Management | 3 | 2024 | 2535 | 0.200 |
Why?
|
Aphasia | 1 | 2024 | 191 | 0.200 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1106 | 0.200 |
Why?
|
Chylous Ascites | 1 | 2022 | 20 | 0.200 |
Why?
|
Recurrent Laryngeal Nerve | 1 | 2024 | 145 | 0.200 |
Why?
|
Neoplasm Proteins | 2 | 2014 | 3596 | 0.200 |
Why?
|
Survival Rate | 11 | 2021 | 12795 | 0.190 |
Why?
|
Cisplatin | 9 | 2016 | 1658 | 0.190 |
Why?
|
Phosphotransferases | 2 | 2021 | 302 | 0.190 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 898 | 0.190 |
Why?
|
Hypertension | 2 | 2020 | 8626 | 0.190 |
Why?
|
Precancerous Conditions | 1 | 2008 | 976 | 0.190 |
Why?
|
Chylothorax | 1 | 2022 | 83 | 0.190 |
Why?
|
Neoplasm Staging | 17 | 2024 | 11206 | 0.190 |
Why?
|
Radiotherapy, Adjuvant | 7 | 2015 | 1776 | 0.190 |
Why?
|
Oncogene Fusion | 1 | 2021 | 84 | 0.180 |
Why?
|
Salvage Therapy | 3 | 2017 | 1272 | 0.180 |
Why?
|
Nuclear Receptor Coactivators | 1 | 2021 | 62 | 0.180 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2023 | 2423 | 0.180 |
Why?
|
Papillomavirus Vaccines | 2 | 2019 | 496 | 0.180 |
Why?
|
Calcitonin | 4 | 2019 | 327 | 0.180 |
Why?
|
Vocal Cord Paralysis | 1 | 2024 | 275 | 0.170 |
Why?
|
Thyroglobulin | 4 | 2014 | 112 | 0.170 |
Why?
|
Disease Progression | 12 | 2023 | 13632 | 0.170 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2020 | 618 | 0.170 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2022 | 5389 | 0.170 |
Why?
|
Iodine | 1 | 2022 | 288 | 0.170 |
Why?
|
Deoxycytidine | 1 | 2024 | 889 | 0.170 |
Why?
|
Liver Neoplasms | 3 | 2023 | 4353 | 0.170 |
Why?
|
Xeroderma Pigmentosum | 1 | 2019 | 31 | 0.170 |
Why?
|
Transaminases | 1 | 2020 | 199 | 0.160 |
Why?
|
Retrospective Studies | 22 | 2025 | 81514 | 0.160 |
Why?
|
Radiopharmaceuticals | 4 | 2023 | 2699 | 0.160 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 416 | 0.160 |
Why?
|
Antibodies, Monoclonal | 5 | 2016 | 9249 | 0.160 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2019 | 110 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 219 | 0.160 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3655 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 3 | 2023 | 4520 | 0.160 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 330 | 0.150 |
Why?
|
Oximes | 2 | 2022 | 305 | 0.150 |
Why?
|
Young Adult | 14 | 2024 | 59889 | 0.150 |
Why?
|
Triazines | 1 | 2020 | 307 | 0.150 |
Why?
|
Tretinoin | 1 | 2021 | 524 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 878 | 0.150 |
Why?
|
Paclitaxel | 7 | 2016 | 1728 | 0.150 |
Why?
|
Survival Analysis | 6 | 2021 | 10070 | 0.140 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2018 | 3537 | 0.140 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 639 | 0.140 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2567 | 0.140 |
Why?
|
DNA, Mitochondrial | 2 | 2023 | 869 | 0.140 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1731 | 0.140 |
Why?
|
Radiation Oncology | 1 | 2023 | 569 | 0.140 |
Why?
|
Tracheotomy | 1 | 2018 | 174 | 0.140 |
Why?
|
Biopsy, Fine-Needle | 3 | 2020 | 1133 | 0.130 |
Why?
|
Activin Receptors, Type II | 1 | 2016 | 122 | 0.130 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2023 | 1624 | 0.120 |
Why?
|
Estrogen Receptor alpha | 1 | 2019 | 578 | 0.120 |
Why?
|
Prognosis | 14 | 2023 | 29922 | 0.120 |
Why?
|
ras Proteins | 2 | 2020 | 1053 | 0.120 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2019 | 4642 | 0.120 |
Why?
|
Anemia | 1 | 2024 | 1511 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 385 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2024 | 0.120 |
Why?
|
Immunoglobulin Fc Fragments | 1 | 2016 | 287 | 0.110 |
Why?
|
Oncogenes | 1 | 2020 | 1235 | 0.110 |
Why?
|
Blood Pressure Determination | 1 | 2018 | 647 | 0.110 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1229 | 0.110 |
Why?
|
Human papillomavirus 16 | 1 | 2016 | 268 | 0.110 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 920 | 0.110 |
Why?
|
Proteinuria | 1 | 2017 | 607 | 0.110 |
Why?
|
Time Factors | 8 | 2021 | 40065 | 0.110 |
Why?
|
Trypsin Inhibitor, Bowman-Birk Soybean | 1 | 2013 | 3 | 0.110 |
Why?
|
Placebos | 1 | 2018 | 1659 | 0.110 |
Why?
|
Trypsin Inhibitors | 1 | 2013 | 32 | 0.110 |
Why?
|
Recovery of Function | 1 | 2024 | 2966 | 0.110 |
Why?
|
Protein Kinases | 1 | 2020 | 1611 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2013 | 10729 | 0.100 |
Why?
|
Leukoplakia, Oral | 1 | 2013 | 79 | 0.100 |
Why?
|
Whole Body Imaging | 1 | 2014 | 281 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2014 | 904 | 0.100 |
Why?
|
Immunotherapy | 3 | 2025 | 4752 | 0.100 |
Why?
|
Exanthema | 1 | 2017 | 502 | 0.100 |
Why?
|
Cranial Nerve Diseases | 1 | 2012 | 111 | 0.100 |
Why?
|
Ischemic Attack, Transient | 1 | 2017 | 870 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 2 | 2024 | 1510 | 0.100 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 483 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1774 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2021 | 2878 | 0.090 |
Why?
|
Skull Neoplasms | 1 | 2012 | 173 | 0.090 |
Why?
|
Gallbladder | 1 | 2013 | 308 | 0.090 |
Why?
|
Fluorouracil | 7 | 2016 | 1648 | 0.090 |
Why?
|
Deglutition Disorders | 2 | 2008 | 639 | 0.090 |
Why?
|
Lymphatic Diseases | 1 | 2013 | 317 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1802 | 0.090 |
Why?
|
Capsid Proteins | 1 | 2014 | 467 | 0.090 |
Why?
|
Paralysis | 1 | 2012 | 248 | 0.090 |
Why?
|
Diagnosis, Differential | 3 | 2024 | 12976 | 0.090 |
Why?
|
Genotype | 4 | 2014 | 13024 | 0.090 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4850 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2329 | 0.090 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2024 | 617 | 0.090 |
Why?
|
Oncogene Proteins | 1 | 2014 | 710 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2016 | 647 | 0.080 |
Why?
|
Hedgehog Proteins | 1 | 2014 | 774 | 0.080 |
Why?
|
Quality of Life | 6 | 2024 | 13462 | 0.080 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2010 | 104 | 0.080 |
Why?
|
Fatigue | 1 | 2017 | 1549 | 0.080 |
Why?
|
Opportunistic Infections | 1 | 2012 | 376 | 0.080 |
Why?
|
Thyrotropin | 1 | 2013 | 841 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9525 | 0.080 |
Why?
|
Gene Expression | 2 | 2019 | 7584 | 0.080 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2009 | 52 | 0.080 |
Why?
|
Treatment Failure | 1 | 2015 | 2652 | 0.080 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2019 | 3111 | 0.080 |
Why?
|
Amifostine | 2 | 2009 | 39 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 2 | 2016 | 3737 | 0.080 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 130 | 0.080 |
Why?
|
Tumor Microenvironment | 2 | 2019 | 3946 | 0.080 |
Why?
|
Retreatment | 3 | 2017 | 598 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 2033 | 0.080 |
Why?
|
Esophageal Stenosis | 2 | 2010 | 196 | 0.070 |
Why?
|
Angiogenesis Inhibitors | 3 | 2016 | 2056 | 0.070 |
Why?
|
Neck | 1 | 2013 | 733 | 0.070 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2009 | 158 | 0.070 |
Why?
|
Neck Dissection | 2 | 2006 | 200 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1831 | 0.070 |
Why?
|
Biological Therapy | 1 | 2008 | 140 | 0.070 |
Why?
|
Carbazoles | 2 | 2019 | 229 | 0.070 |
Why?
|
Lymphatic Metastasis | 4 | 2024 | 2887 | 0.070 |
Why?
|
Tonsillar Neoplasms | 1 | 2007 | 49 | 0.070 |
Why?
|
Gestational Age | 1 | 2016 | 3609 | 0.070 |
Why?
|
Relative Biological Effectiveness | 1 | 2008 | 299 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10383 | 0.070 |
Why?
|
Otorhinolaryngologic Neoplasms | 1 | 2006 | 26 | 0.070 |
Why?
|
Ki-67 Antigen | 1 | 2008 | 629 | 0.070 |
Why?
|
Adolescent | 6 | 2022 | 88835 | 0.070 |
Why?
|
Technology, Pharmaceutical | 1 | 2006 | 83 | 0.060 |
Why?
|
Cyclooxygenase 2 | 1 | 2008 | 594 | 0.060 |
Why?
|
Dinoprostone | 1 | 2008 | 591 | 0.060 |
Why?
|
Brain | 1 | 2012 | 27171 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2453 | 0.060 |
Why?
|
DNA Damage | 1 | 2015 | 2457 | 0.060 |
Why?
|
Meta-Analysis as Topic | 2 | 2008 | 1370 | 0.060 |
Why?
|
Radiotherapy, Conformal | 1 | 2008 | 533 | 0.060 |
Why?
|
Hypopharynx | 1 | 2004 | 53 | 0.060 |
Why?
|
Incidence | 3 | 2019 | 21480 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 3 | 2024 | 20659 | 0.050 |
Why?
|
Xerostomia | 3 | 2010 | 94 | 0.050 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2024 | 192 | 0.050 |
Why?
|
Melanoma | 1 | 2022 | 5719 | 0.050 |
Why?
|
Lipid Peroxides | 1 | 2023 | 73 | 0.050 |
Why?
|
Radiation-Protective Agents | 1 | 2003 | 87 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3529 | 0.050 |
Why?
|
Larynx | 1 | 2008 | 491 | 0.050 |
Why?
|
Oxyphil Cells | 1 | 2023 | 55 | 0.050 |
Why?
|
Tropomyosin | 1 | 2023 | 103 | 0.050 |
Why?
|
Radiation Injuries | 2 | 2008 | 1181 | 0.050 |
Why?
|
Oligonucleotides | 3 | 2013 | 561 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2024 | 260 | 0.050 |
Why?
|
Fermentation | 1 | 2023 | 141 | 0.050 |
Why?
|
Administration, Oral | 2 | 2014 | 4015 | 0.050 |
Why?
|
Gastroscopy | 1 | 2004 | 213 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 220 | 0.050 |
Why?
|
Pain | 2 | 2022 | 5077 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2017 | 5302 | 0.050 |
Why?
|
Neoplasms, Second Primary | 1 | 2010 | 1050 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5772 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2018 | 9071 | 0.050 |
Why?
|
Pilot Projects | 3 | 2017 | 8733 | 0.050 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 17075 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2016 | 1701 | 0.050 |
Why?
|
Radiotherapy Dosage | 4 | 2010 | 2865 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 1410 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2005 | 700 | 0.050 |
Why?
|
Immunohistochemistry | 3 | 2021 | 11022 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2013 | 3454 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3458 | 0.050 |
Why?
|
Remission Induction | 2 | 2006 | 2411 | 0.050 |
Why?
|
Thyroid Function Tests | 1 | 2022 | 293 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8875 | 0.040 |
Why?
|
Algorithms | 1 | 2021 | 14071 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6942 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2021 | 312 | 0.040 |
Why?
|
Signal Transduction | 4 | 2019 | 23601 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 1994 | 388 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 5526 | 0.040 |
Why?
|
Databases, Factual | 3 | 2021 | 8067 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2019 | 5849 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3608 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2022 | 384 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5993 | 0.040 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2021 | 347 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2692 | 0.040 |
Why?
|
Laryngoscopy | 1 | 2004 | 686 | 0.040 |
Why?
|
Mental Disorders | 1 | 2019 | 6853 | 0.040 |
Why?
|
Poly I-C | 1 | 2019 | 110 | 0.040 |
Why?
|
Phenotype | 2 | 2020 | 16721 | 0.040 |
Why?
|
Mass Screening | 1 | 2014 | 5446 | 0.040 |
Why?
|
Risk Assessment | 4 | 2018 | 24282 | 0.040 |
Why?
|
Haploidy | 1 | 2018 | 128 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 2 | 2016 | 616 | 0.040 |
Why?
|
Cohort Studies | 4 | 2020 | 41649 | 0.040 |
Why?
|
Injections, Intramuscular | 1 | 2019 | 552 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2017 | 39193 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 862 | 0.040 |
Why?
|
Annual Reports as Topic | 1 | 2017 | 36 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12509 | 0.030 |
Why?
|
Therapeutics | 1 | 2017 | 113 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21056 | 0.030 |
Why?
|
Clonal Anergy | 1 | 2017 | 169 | 0.030 |
Why?
|
International Agencies | 1 | 2017 | 240 | 0.030 |
Why?
|
Pyridones | 1 | 2022 | 816 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2020 | 453 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2017 | 126 | 0.030 |
Why?
|
Platinum Compounds | 1 | 2017 | 94 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2022 | 864 | 0.030 |
Why?
|
Prospective Studies | 5 | 2024 | 54802 | 0.030 |
Why?
|
United States | 6 | 2022 | 72903 | 0.030 |
Why?
|
Tyrosine | 1 | 2020 | 1428 | 0.030 |
Why?
|
Propensity Score | 1 | 2024 | 1968 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 26346 | 0.030 |
Why?
|
Societies, Medical | 2 | 2018 | 3956 | 0.030 |
Why?
|
Breast | 1 | 2024 | 1946 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2019 | 1347 | 0.030 |
Why?
|
Animals | 9 | 2020 | 168764 | 0.030 |
Why?
|
Amygdala | 1 | 2023 | 1377 | 0.030 |
Why?
|
Drug Approval | 1 | 2022 | 818 | 0.030 |
Why?
|
Laryngectomy | 2 | 2009 | 244 | 0.030 |
Why?
|
Stroke | 1 | 2017 | 9747 | 0.030 |
Why?
|
DNA, Viral | 1 | 2022 | 2199 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2009 | 723 | 0.030 |
Why?
|
Sulindac | 1 | 2014 | 29 | 0.030 |
Why?
|
Stomatitis | 2 | 2009 | 270 | 0.030 |
Why?
|
Kinetics | 1 | 2022 | 6274 | 0.030 |
Why?
|
Guanine Nucleotide Dissociation Inhibitors | 1 | 1993 | 23 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2022 | 1672 | 0.030 |
Why?
|
Cytoskeletal Proteins | 1 | 2019 | 1325 | 0.030 |
Why?
|
Dyspnea | 1 | 2022 | 1352 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 752 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2019 | 1250 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2019 | 1555 | 0.030 |
Why?
|
Telomerase | 1 | 2018 | 749 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1084 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2015 | 2593 | 0.030 |
Why?
|
Biopsy | 1 | 2024 | 6763 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2017 | 696 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 545 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 2013 | 337 | 0.020 |
Why?
|
Glioblastoma | 1 | 2007 | 3459 | 0.020 |
Why?
|
Mice | 5 | 2019 | 81819 | 0.020 |
Why?
|
Consensus | 1 | 2022 | 3202 | 0.020 |
Why?
|
Mice, Nude | 1 | 2018 | 3618 | 0.020 |
Why?
|
Cancer Vaccines | 1 | 2019 | 1044 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3432 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2019 | 3160 | 0.020 |
Why?
|
DNA Mutational Analysis | 2 | 2016 | 4108 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2017 | 2627 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2015 | 708 | 0.020 |
Why?
|
Palliative Care | 1 | 2005 | 3645 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2021 | 2968 | 0.020 |
Why?
|
Fungal Proteins | 1 | 1994 | 899 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2045 | 0.020 |
Why?
|
Ligands | 1 | 2016 | 3273 | 0.020 |
Why?
|
GTP-Binding Proteins | 1 | 1993 | 945 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2018 | 6220 | 0.020 |
Why?
|
Receptors, Somatomedin | 1 | 2008 | 57 | 0.020 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 178 | 0.020 |
Why?
|
Doxorubicin | 1 | 2015 | 2230 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4562 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5501 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1394 | 0.020 |
Why?
|
Gene Amplification | 1 | 2012 | 1091 | 0.020 |
Why?
|
Radiotherapy | 1 | 2015 | 1494 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2009 | 682 | 0.020 |
Why?
|
Organ Specificity | 2 | 2008 | 1965 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8501 | 0.020 |
Why?
|
Lymphocytes | 1 | 2015 | 2599 | 0.020 |
Why?
|
Viral Matrix Proteins | 1 | 2009 | 192 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2010 | 426 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6547 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3426 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5881 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2008 | 869 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2016 | 2631 | 0.020 |
Why?
|
Health | 1 | 2009 | 397 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5929 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2009 | 1752 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2017 | 4405 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18380 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5370 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15398 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4528 | 0.010 |
Why?
|
DNA Repair | 1 | 1994 | 2048 | 0.010 |
Why?
|
Cloning, Molecular | 3 | 1994 | 4165 | 0.010 |
Why?
|
Regression Analysis | 1 | 2013 | 6322 | 0.010 |
Why?
|
Risk Factors | 3 | 2018 | 74840 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12056 | 0.010 |
Why?
|
MutS Homolog 2 Protein | 2 | 1994 | 200 | 0.010 |
Why?
|
Genetic Testing | 1 | 2017 | 3595 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2019 | 18973 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1470 | 0.010 |
Why?
|
Pharyngeal Diseases | 1 | 2004 | 133 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20124 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8611 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10429 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 3236 | 0.010 |
Why?
|
Epitopes | 1 | 2009 | 2523 | 0.010 |
Why?
|
Child | 2 | 2021 | 80564 | 0.010 |
Why?
|
Mitosis | 1 | 2007 | 1173 | 0.010 |
Why?
|
Constriction, Pathologic | 1 | 2004 | 1105 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36532 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22332 | 0.010 |
Why?
|
DNA-Binding Proteins | 2 | 1994 | 9601 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2014 | 12768 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2008 | 2056 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 42500 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18293 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2008 | 2880 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 18071 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9338 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2008 | 2207 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2008 | 3430 | 0.010 |
Why?
|
Pedigree | 2 | 1994 | 4526 | 0.010 |
Why?
|
Chromosome Mapping | 2 | 1994 | 4618 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12131 | 0.010 |
Why?
|
Cytokines | 1 | 2009 | 7421 | 0.010 |
Why?
|
Yolk Sac | 1 | 1993 | 79 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3513 | 0.010 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 1994 | 313 | 0.010 |
Why?
|
rac GTP-Binding Proteins | 1 | 1993 | 164 | 0.010 |
Why?
|
cdc42 GTP-Binding Protein | 1 | 1993 | 187 | 0.010 |
Why?
|
Frameshift Mutation | 1 | 1994 | 393 | 0.010 |
Why?
|
Apoptosis | 1 | 2008 | 9514 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 1994 | 13400 | 0.010 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 1993 | 430 | 0.010 |
Why?
|
Introns | 1 | 1994 | 966 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1994 | 17594 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2009 | 22223 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1993 | 1984 | 0.010 |
Why?
|
DNA Primers | 1 | 1994 | 2825 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15880 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1993 | 2745 | 0.010 |
Why?
|
Sequence Alignment | 1 | 1993 | 2171 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1994 | 2341 | 0.010 |
Why?
|
Exons | 1 | 1994 | 2391 | 0.000 |
Why?
|
DNA, Neoplasm | 1 | 1994 | 1742 | 0.000 |
Why?
|
Diet | 1 | 2006 | 8086 | 0.000 |
Why?
|
Biological Evolution | 1 | 1994 | 1072 | 0.000 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1993 | 1560 | 0.000 |
Why?
|
Base Sequence | 1 | 1994 | 12403 | 0.000 |
Why?
|
DNA | 1 | 1994 | 7202 | 0.000 |
Why?
|